To include your compound in the COVID-19 Resource Center, submit it here.

Biogen decreases aducanumab royalty obligations to Neurimmune

Biogen Inc. (NASDAQ:BIIB) reduced its royalty obligations to Neurimmune Holding AG (Schlieren,

Read the full 125 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE